Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1527315

Cover Image

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1527315

Global Urological Disorders Drugs Market Size study, by Drug Type, by Indication, by Distribution Channel and Regional Forecasts 2022-2032

PUBLISHED:
PAGES: 285 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (Enterprise License)
USD 6250

Add to Cart

Global Urological Disorders Drugs Market is valued approximately at USD 9.1 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.95% over the forecast period 2024-2032. The urological disorders drugs market encompasses a broad spectrum of medications aimed at treating various urological conditions, including prostate cancer, bladder cancer, kidney stones, and other disorders. Urological disorders drugs encompass a range of medications designed to treat conditions affecting the urinary tract and male reproductive organs. These disorders include, but are not limited to, urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), overactive bladder (OAB), kidney stones, erectile dysfunction, and bladder cancer. The drugs used in treating these conditions vary widely, including antibiotics for infections, alpha-blockers and 5-alpha-reductase inhibitors for BPH, antimuscarinics and beta-3 agonists for OAB, and phosphodiesterase inhibitors for erectile dysfunction. The development of these drugs is driven by the increasing prevalence of urological conditions, an aging population, and advancements in medical research that provide better understanding and management of these disorders. The market for urological disorders drugs is expanding as new treatments and therapies continue to be developed, offering improved efficacy and safety profiles for patients.

The rising geriatric population significantly contributes to market growth, as aging is associated with a higher prevalence of urological disorders such as prostate and bladder cancers. This demographic shift drives the demand for effective therapeutic options. Additionally, lifestyle changes, dietary habits, and exposure to environmental toxins are escalating the incidence of urological disorders, further bolstering market growth. Advances in technology and the development of novel treatment options, including targeted therapies, immunotherapies, and gene therapies, present substantial opportunities for market expansion. Despite these opportunities, the market faces challenges such as the high cost of urological drugs, which can limit accessibility, particularly in developing regions. Moreover, stringent regulatory frameworks and approval processes pose barriers to the rapid introduction of new drugs, potentially stifling innovation and market growth.

The key regions considered for the Global Urological Disorders Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. The regional analysis of the market reveals that the Americas hold a dominant position due to the high prevalence of urological disorders and the presence of key market players. Meanwhile, the Asia-Pacific region is poised for significant growth, driven by a rising geriatric population and improving healthcare infrastructure.

Major market players included in this report are:

  • AbbVie
  • Astellas Pharma
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffmann-La Roche
  • GSK
  • Ipsen Biopharmaceuticals
  • Johnson & Johnson
  • Kyowa Kirin
  • Mylan
  • Novartis
  • Pfizer
  • Sanofi
  • Sun Pharmaceutical Industries

The detailed segments and sub-segment of the market are explained below:

By Drug Type:

  • Hormone Therapy Drugs
  • Chemotherapy Drugs
  • Immunotherapy Drugs
  • Antibiotics
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

By Indication:

  • Prostate Cancer
  • Bladder Cancer
  • Kidney Stones
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with country-level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand-side and supply-side analysis of the market.

Table of Contents

Chapter 1. Global Urological Disorders Drugs Market Executive Summary

  • 1.1. Global Urological Disorders Drugs Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Drug Type
    • 1.3.2. By Indication
    • 1.3.3. By Distribution Channel
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Urological Disorders Drugs Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory Frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Urological Disorders Drugs Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Growing Geriatric Population
    • 3.1.2. Increasing Prevalence of Urological Disorders
  • 3.2. Market Challenges
    • 3.2.1. High Cost of Drugs
    • 3.2.2. Stringent Regulatory Frameworks
  • 3.3. Market Opportunities
    • 3.3.1. Adoption of Advanced Treatment Options

Chapter 4. Global Urological Disorders Drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top investment opportunity
  • 4.4. Top winning strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Urological Disorders Drugs Market Size & Forecasts by Drug Type (2022-2032)

  • 5.1. Segment Dashboard
  • 5.2. Global Urological Disorders Drugs Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Hormone Therapy Drugs
    • 5.2.2. Chemotherapy Drugs
    • 5.2.3. Immunotherapy Drugs
    • 5.2.4. Antibiotics
    • 5.2.5. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Chapter 6. Global Urological Disorders Drugs Market Size & Forecasts by Indication (2022-2032)

  • 6.1. Segment Dashboard
  • 6.2. Global Urological Disorders Drugs Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Prostate Cancer
    • 6.2.2. Bladder Cancer
    • 6.2.3. Kidney Stones
    • 6.2.4. Others

Chapter 7. Global Urological Disorders Drugs Market Size & Forecasts by Distribution Channel (2022-2032)

  • 7.1. Segment Dashboard
  • 7.2. Global Urological Disorders Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Retail Pharmacies
    • 7.2.3. Online Pharmacies

Chapter 8. Global Urological Disorders Drugs Market Size & Forecasts by Region (2022-2032)

  • 8.1. North America Urological Disorders Drugs Market
    • 8.1.1. U.S. Urological Disorders Drugs Market
      • 8.1.1.1. Drug Type breakdown size & forecasts, 2022-2032
      • 8.1.1.2. Indication breakdown size & forecasts, 2022-2032
      • 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
    • 8.1.2. Canada Urological Disorders Drugs Market
  • 8.2. Europe Urological Disorders Drugs Market
    • 8.2.1. U.K. Urological Disorders Drugs Market
    • 8.2.2. Germany Urological Disorders Drugs Market
    • 8.2.3. France Urological Disorders Drugs Market
    • 8.2.4. Spain Urological Disorders Drugs Market
    • 8.2.5. Italy Urological Disorders Drugs Market
    • 8.2.6. Rest of Europe Urological Disorders Drugs Market
  • 8.3. Asia-Pacific Urological Disorders Drugs Market
    • 8.3.1. China Urological Disorders Drugs Market
    • 8.3.2. India Urological Disorders Drugs Market
    • 8.3.3. Japan Urological Disorders Drugs Market
    • 8.3.4. Australia Urological Disorders Drugs Market
    • 8.3.5. South Korea Urological Disorders Drugs Market
    • 8.3.6. Rest of Asia Pacific Urological Disorders Drugs Market
  • 8.4. Latin America Urological Disorders Drugs Market
    • 8.4.1. Brazil Urological Disorders Drugs Market
    • 8.4.2. Mexico Urological Disorders Drugs Market
    • 8.4.3. Rest of Latin America Urological Disorders Drugs Market
  • 8.5. Middle East & Africa Urological Disorders Drugs Market
    • 8.5.1. Saudi Arabia Urological Disorders Drugs Market
    • 8.5.2. South Africa Urological Disorders Drugs Market
    • 8.5.3. Rest of Middle East & Africa Urological Disorders Drugs Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. AbbVie
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Market Strategies
    • 9.3.2. Astellas Pharma
    • 9.3.3. Bayer
    • 9.3.4. Bristol-Myers Squibb
    • 9.3.5. Eli Lilly
    • 9.3.6. F. Hoffmann-La Roche
    • 9.3.7. GSK
    • 9.3.8. Ipsen Biopharmaceuticals
    • 9.3.9. Johnson & Johnson
    • 9.3.10. Kyowa Kirin
    • 9.3.11. Mylan
    • 9.3.12. Novartis
    • 9.3.13. Pfizer
    • 9.3.14. Sanofi
    • 9.3.15. Sun Pharmaceutical Industries

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!